JP2024517765A5 - - Google Patents
Info
- Publication number
- JP2024517765A5 JP2024517765A5 JP2023566804A JP2023566804A JP2024517765A5 JP 2024517765 A5 JP2024517765 A5 JP 2024517765A5 JP 2023566804 A JP2023566804 A JP 2023566804A JP 2023566804 A JP2023566804 A JP 2023566804A JP 2024517765 A5 JP2024517765 A5 JP 2024517765A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- approximately
- plasma
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182757P | 2021-04-30 | 2021-04-30 | |
| US63/182,757 | 2021-04-30 | ||
| PCT/US2022/072013 WO2022232838A1 (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517765A JP2024517765A (ja) | 2024-04-23 |
| JP2024517765A5 true JP2024517765A5 (https=) | 2025-05-09 |
Family
ID=83848780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566804A Pending JP2024517765A (ja) | 2021-04-30 | 2022-04-29 | インテグリン阻害剤の拡大投与レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230028658A1 (https=) |
| EP (1) | EP4329755A4 (https=) |
| JP (1) | JP2024517765A (https=) |
| KR (1) | KR20240024060A (https=) |
| CN (1) | CN117615760A (https=) |
| AU (1) | AU2022265730A1 (https=) |
| CA (1) | CA3173787A1 (https=) |
| CL (1) | CL2023003219A1 (https=) |
| CO (1) | CO2023016295A2 (https=) |
| CR (1) | CR20230553A (https=) |
| IL (1) | IL308063A (https=) |
| MX (1) | MX2023012794A (https=) |
| TW (1) | TW202308637A (https=) |
| WO (1) | WO2022232838A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| WO2019118938A1 (en) * | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| CN114173803A (zh) * | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TW202329973A (zh) * | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
-
2022
- 2022-04-29 MX MX2023012794A patent/MX2023012794A/es unknown
- 2022-04-29 IL IL308063A patent/IL308063A/en unknown
- 2022-04-29 WO PCT/US2022/072013 patent/WO2022232838A1/en not_active Ceased
- 2022-04-29 US US17/733,488 patent/US20230028658A1/en not_active Abandoned
- 2022-04-29 CR CR20230553A patent/CR20230553A/es unknown
- 2022-04-29 JP JP2023566804A patent/JP2024517765A/ja active Pending
- 2022-04-29 EP EP22796995.3A patent/EP4329755A4/en not_active Withdrawn
- 2022-04-29 CN CN202280046288.9A patent/CN117615760A/zh active Pending
- 2022-04-29 KR KR1020237041401A patent/KR20240024060A/ko not_active Withdrawn
- 2022-04-29 TW TW111116506A patent/TW202308637A/zh unknown
- 2022-04-29 AU AU2022265730A patent/AU2022265730A1/en not_active Abandoned
- 2022-04-29 CA CA3173787A patent/CA3173787A1/en active Pending
-
2023
- 2023-10-26 CL CL2023003219A patent/CL2023003219A1/es unknown
- 2023-11-29 CO CONC2023/0016295A patent/CO2023016295A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517765A5 (https=) | ||
| JP2022526818A5 (https=) | ||
| JP2021529755A5 (https=) | ||
| JP2021119140A5 (https=) | ||
| JP2022508657A5 (https=) | ||
| JP4673977B2 (ja) | 炎症性疾患治療用フタラジン誘導体 | |
| JP7012152B2 (ja) | Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤 | |
| CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
| US6432950B1 (en) | Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives | |
| US9511060B2 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| JP2019510787A5 (https=) | ||
| JP2023524970A5 (https=) | ||
| JP2021521200A5 (https=) | ||
| JP2016172739A5 (https=) | ||
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
| EA027689B1 (ru) | Трифторметилзамещенные аннелированные пиримидины и их применение | |
| IL262708A (en) | Pretty metamorphous compounds of pyrazole for the treatment of diseases | |
| JP2022529371A5 (https=) | ||
| CN104557904A (zh) | 运动障碍治疗剂 | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| JP2021512075A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| JP2023550902A5 (https=) | ||
| PT95978B (pt) | Processo para de novos derivados do 6-aril-5,6-dihidroimidazo/2,l-b/-tiazol comefeito imuno-estimulante | |
| TWI864050B (zh) | 環狀去氧核糖核苷酸化合物 |